Pharma Focus Asia

Novo Nordisk Invests US$2.3 billion (DKK 15.9 billion) to Expand Manufacturing Facilities

Novo Nordisk plans for the expansion of current Active Pharmaceutical Ingredient (API) production facility in Denmark. This expansion supports the development of future portfolio of treatments for serious chronic diseases.

Features:

The new facility, covering approximately 65,000 square meters, will be designed as a multi-product facility with flexibility to accommodate new processes and incorporate state-of-the-art technology and a modern working environment.

This investment in additional production capacity aims to ensure the continuous development of the late-phase pipeline and deliver important medicines for the treatment of serious chronic diseases. 

The focus on creating a future-proof and cost-effective facility reflects the commitment in delivering the highest quality to patients in an efficient and environmentally sustainable manner.

With construction already underway, the facility is expected to commence API production by early 2029. 

Upon completion of the expansion project estimates to generate 340 new jobs and the facility will be fully equipped.

Specifications:

Name         Novo Nordisk
Type           Expansion
Budget       US$2.3 billion (DKK 15.9 billion)
Year           2029

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference